TM6008 is a prolyl hydroxylase (PHD) inhibitor that protects against cell death after hypoxia. TM6008 suppresses the activity of PHDs, inducing continuous HIF-1α activation. Immunoblotting revealed that TM6008 increased the expression of HIF-1α, HIF-2α and vascular endothelial growth factor in myocarditis.
In vivo, TM6008 improved left ventricular ejection fraction significantly on the 21st day of EAM. Though TM6008 did not affect the severity of myocardial cell infiltration, it tended to reduce cardiac fibrosis. Immunohistochemistry showed that CD31-positive blood vessels were preserved in the TM6008 group compared to the control group. Immunoblotting revealed that TM6008 increased the expression of HIF-1α, HIF-2α and vascular endothelial growth factor in myocarditis. Oral administration of TM6008 protected neurons in a model of cerebrovascular disease.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Neovascularization induced by hypoxia inducible transcription factor is associated with the improvement of cardiac dysfunction in experimental autoimmune myocarditis.
Tada Y, et al. Expert Opin Investig Drugs. 2014 Feb;23(2):149-62. PMID: 24205804.
A novel prolyl hydroxylase inhibitor protects against cell death after hypoxia.
Kontani S, et al. Neurochem Res. 2013 Dec;38(12):2588-94. PMID: 24132642.
[Novel neuroprotective agents: a HIF activator and an Akt activator].
Takizawa S, et al. Rinsho Shinkeigaku. 2012;52(11):911-2. PMID: 23196464.
Inhibition of prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-alpha expression.
Takeda K, et al. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2132-7. PMID: 19762779.
A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia.
Nangaku M, et al. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2548-54. PMID: 17932321.
ML-281 is a potent ans selective STK33 inhibitor with IC50 value of 14 nM.
ML-265 (TEPP-46) is a potent and selective activator of recombinant pyruvate kinase M2 (PKM2).
LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor, with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Compstatinis is a 13-residue cyclic peptide, binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.
Azaserine is an inhibitor of the rate limiting step of the hexosamine biosynthethic pathway (HBP) and an irreversible inhibitor of GGT1 (gamma-Glutamyltranspeptidase).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.